Metabolic reprogramming-driven resistance to multi-kinase inhibitors in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities

Puntos clave

• Resistance to multi-kinase inhibitors was significantly linked to changes in metabolic reprogramming, impacting treatment efficacy.
• Key evidence showed that alterations in metabolic pathways were present in 70% of hepatocellular carcinoma samples analyzed.
• Analysis of molecular mechanisms revealed critical pathways contributing to therapeutic resistance in hepatocellular carcinoma.
• This highlights the need for novel intervention strategies targeting metabolic aspects in hepatocellular carcinoma treatment.